+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials



Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials



Clinical and Experimental Pharmacology and Physiology 40(3): 219-226



The combination of fenofibrate with statins is a beneficial therapeutic option for patients with mixed dyslipidaemia, but concerns about adverse events (AEs) make physicians reluctant to use this combination therapy. Medline, Embase and the Cochrane Library were searched to identify 13 randomized controlled trials, involving 7712 patients, of statin-fenofibrate therapy versus statin alone for review. There were significant decreases in low-density lipoprotein-cholesterol, triglycerides and total cholesterol and increases in high-density lipoprotein-cholesterol in patients receiving combination therapy compared with statin therapy alone. The incidence of aminotransferase elevations in the fenofibrate-statin therapy group was significantly higher than in the statin monotherapy group (odds ratio (OR), 1.66; 95% confidence interval (CI) 1.17-2.37; P < 0.05). The incidence of elevated creatine kinase levels (OR 0.88; 95% CI 0.63-1.23; P > 0.05), muscle-associated AEs (OR 0.98; 95% CI 0.88-1.09; P > 0.05) and withdrawals attributed to liver and muscle dysfunction did not differ significantly between the two groups. The efficacy of fenofibrate + standard-dose statin and incidence of AEs in the fenofibrate + standard-dose statin group were almost identical to those in the fenofibrate-statin group. In conclusion, combination therapy improves the blood lipid profile of patients. Fenofibrate-statin combination therapy appears to be as well tolerated as statin monotherapy. Physicians should consider fenofibrate-statin combination therapy in patients but monitor aminotransferase levels to avoid hepatic complications.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051403410

Download citation: RISBibTeXText

PMID: 23324122

DOI: 10.1111/1440-1681.12053


Related references

Adverse Events of Statin-Fenofibrate Therapy versus Statin Alone A Meta-analysis of Randomized Controlled Trials. 2013

Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion 29(3): 181-188, 2013

A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. European Review for Medical and Pharmacological Sciences 23(5): 2302-2310, 2019

Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy. Current Medical Research and Opinion 31(12): 2273-2285, 2015

Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. International Journal of Cardiology 191: 138-148, 2015

Statin Antiarrhythmic Effect on Atrial Fibrillation in Statin-Naive Patients Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology and Therapeutics 21(2): 167-176, 2016

Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: a meta-analysis of randomized trials. Journal of Cardiovascular Pharmacology and Therapeutics 17(4): 357-365, 2012

Perioperative statin therapy in cardiac surgery: a meta-analysis of randomized controlled trials. Critical Care 20(1): 395, 2016

Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. European Journal of Epidemiology 25(1): 29-35, 2010

Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 43(8): 2149-2156, 2012

Can Statin Therapy Reduce the Risk of Melanoma? A Meta-Analysis of Randomized Controlled Trials. European Journal of Epidemiology 25(1): 29-35, 2010

Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. PharmacoTherapy 31(11): 1051-1062, 2011

The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. British Journal of Clinical Pharmacology 74(5): 744-756, 2012

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Archives of Internal Medicine 166(21): 2307-2313, 2006

Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. Clinical and Experimental Hypertension 40(7): 601-608, 2018